Cantharidin in-situ release pharmaceutical composition and preparation method thereof

The preparation of a cantharidin in situ release drug composition solves the problems of short drug release time and skin damage in the treatment of molluscum contagiosum, achieving long-term drug release within the wart and reducing skin damage, thus providing a more effective treatment option.

CN121059523APending Publication Date: 2025-12-05ZHUOHE PHARM GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511529636.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-24
Publication Date
2025-12-05

AI Technical Summary

Technical Problem

Existing technologies for treating molluscum contagiosum use drugs with short release times, poor therapeutic effects, and local treatment methods can damage the surrounding skin.

Method used

A cantharidin in situ release drug composition is used, comprising an active ingredient, a gel matrix, a stabilizer, an antibacterial agent, and a solvent, to prepare an in situ gel formulation. It is administered via subcutaneous injection or topical application, utilizing temperature changes to convert the drug into a gel state locally, prolonging the drug release time, enhancing the therapeutic effect, and reducing damage to the surrounding skin.

Benefits of technology

The drug prolongs its release time within the local wart, enhancing the therapeutic effect while reducing damage to the surrounding skin, providing a more stable treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a cantharidin in-situ release pharmaceutical composition and a preparation method thereof. The pharmaceutical composition contains 0.1-2% of an active component, 0.5-3% of a gel matrix, 0.1-3% of a stabilizer, 0.1-1% of a bacteriostatic agent and a solvent, the active component comprises cantharidin or a derivative thereof. The in-situ gel preparation provided by the invention can be an injection preparation and also can be applied externally. The injection preparation is liquid at normal temperature, when the injection preparation is injected subcutaneously, due to temperature rise, the liquid injection preparation is converted into a gel state, the release time of the medicine in local warts is prolonged, and the treatment effect is enhanced. During external administration, the medicine is coated on a molluscum contagiosum body, and the medicine can be quickly converted into gel under the action of temperature, so that the medicine is convenient to smear and can be effectively prevented from overflowing, and the damage of the medicine to surrounding skin is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical formulation technology, and more specifically to a cantharidin in situ release pharmaceutical composition and its preparation method. Background Technology

[0002] Molluscum contagiosum, commonly known as "water monkey" or "mouse milk" in traditional Chinese medicine, is a viral infectious skin disease. It can be transmitted through direct and indirect contact. Molluscum contagiosum can occur anywhere on the body, but in children and adults infected through non-sexual contact, it is most common on the neck, back, face, limbs, and buttocks. It can also occur on the genitals, pubic area, inner thighs, or perianal region.

[0003] The causative agent of this disease is molluscum contagiosum virus, a poxvirus. It is brick-shaped, approximately 300 nm × 300 nm in size, and can be seen under a regular microscope. Its structure is similar to that of smallpox virus, with DNA as its nucleic acid, a completely symmetrical capsid, and an envelope.

[0004] The main route of transmission for molluscum contagiosum is direct contact, but it can also be transmitted through autoinoculation. It often spreads in public bathhouses, hotels, restaurants, or swimming pools. Some believe that individuals with a family history of molluscum contagiosum are more susceptible to the virus and more prone to widespread infection.

[0005] The incubation period for this disease is 2-3 weeks. Patients who have been in contact with molluscum contagiosum will develop symptoms after this incubation period. The number of lesions varies, scattered and not fused together. There are 3-5 to dozens of molluscum contagiosum lesions, scattered and not fused, with mild itching. Scratching can cause self-propagation, producing more new molluscum contagiosum lesions along the scratched area and surrounding tissue. In cases of immunodeficiency, or with the use of immunosuppressants and corticosteroids, the rash can become widespread. A white, cheesy substance, called a "mollusc body," can be squeezed out when the center of the apex of a molluscum contagiosum lesion is punctured; this is a characteristic lesion of the disease. In a few patients, the lesions may occasionally keratinize, resembling small cutaneous horns; this is called "keratotic molluscum contagiosum." Lesions can sometimes grow to 10-15 mm in size. These large lesions are usually solitary and often develop secondary bacterial infections leading to inflammation; some lesions can even persist for more than 5 years. Mild itching is common, and scratching can lead to secondary infections, resulting in pustular lesions and even more serious diseases such as nephritis.

[0006] Treatment for molluscum contagiosum is generally localized. After puncturing the wart, apply 2%-2.5% iodine tincture or other antiviral medications, such as phthalimide cream or 5-fluorouracil. Apply the medication directly to the tip of the wart, taking care to protect the surrounding skin. These medications have a short release time and are not very effective.

[0007] Liquid nitrogen freezing treatment can also be used, in which a freezer sprays liquid nitrogen on the surface of the wart, eventually causing the wart to fall off. This method is not suitable for the treatment of multiple warts. In addition, molluscum can also be treated with traditional Chinese medicine, but the treatment time is long and the effect is not good.

[0008] Therefore, there is an urgent need for a new preparation for treating molluscum. SUMMARY

[0009] To solve the above problems, the present application provides a cantharidin in situ release pharmaceutical composition and a preparation method thereof. The pharmaceutical composition is a simple and stable in situ release drug, which can prolong the release time in the local wart and enhance the treatment effect.

[0010] The present application discloses a cantharidin in situ release pharmaceutical composition, which contains 0.1-2% active ingredient, 0.5-3% gel matrix, 0.1-3% stabilizer, 0.1-1% bacteriostatic agent and solvent; the active ingredient contains cantharidin or its derivative.

[0011] Preferably, the active ingredient is one or more of sodium cantharidate, norcantharidin, methylcantharidin and hydroxycantharidin.

[0012] Preferably, the gel matrix is one or a combination of poloxamer 407 and poloxamer 188.

[0013] Preferably, the stabilizer is a mixture of one or more of edetate disodium, sodium bisulfite, sodium sulfite, sodium metabisulfite and butylated hydroxytoluene.

[0014] Preferably, the bacteriostatic agent is one or more of phenol, cresol, chlorocresol, chlorobutanol, phenylmercuric nitrate, benzyl alcohol and nipagin.

[0015] Preferably, the solvent is one or more of water, ethanol, isopropyl alcohol and acetone.

[0016] Preferably, the pharmaceutical composition is an in situ gel preparation.

[0017] The present application also discloses a preparation method of the above-mentioned cantharidin in situ release pharmaceutical composition, which comprises the following steps: S1. In a sterile environment, take 80% of the prescribed amount of solvent, add stabilizer, then add appropriate amount of ethanol solution, stir uniformly, and perform sterile filtration; S2. Dissolve the gel matrix in the solution of step S1, stir until the liquid is clear and uniform, and control the process temperature at 10-20℃; S3. In a sterile environment, control the water temperature at 10-20℃; add appropriate amount of solvent to the active ingredient to dissolve it, then add bacteriostatic agent and stabilizer, stir to dissolve, and perform sterile filtration; S4, mixing the two solutions of steps S2 and S3, stirring uniformly, to obtain the cantharidin in-situ release pharmaceutical composition.

[0018] Compared with the prior art, the cantharidin in-situ release pharmaceutical composition has the following advantages: The in-situ gel preparation can be an injection preparation or an external use preparation.

[0019] When the subcutaneous local injection is used to treat molluscum contagiosum, the injection preparation is a liquid at room temperature, and the liquid injection preparation is converted into a gel state due to the temperature rise when the injection is injected subcutaneously, so that the drug is released for a long time in the local wart body, and the treatment effect is enhanced.

[0020] When the external use is used to treat molluscum contagiosum, the drug is applied to the wart body of molluscum contagiosum by using a micro-quantitative drug delivery device, and the drug is quickly converted into a gel state under the action of temperature, so that the drug can be conveniently applied and effectively prevented from overflowing, thereby reducing the damage of the drug to the surrounding skin. DETAILED DESCRIPTION

[0021] The technical solutions in the embodiments of the present application will be clearly and completely described below. Obviously, the described embodiments are only some of the embodiments of the present application, but not all the embodiments.

[0022] The present application discloses a cantharidin in-situ release pharmaceutical composition, which is an in-situ gel preparation. The pharmaceutical composition contains 0.1-2% of active ingredients, 0.5-3% of gel matrix, 0.1-3% of stabilizers, 0.1-1% of bacteriostatic agents and solvents; the active ingredients include cantharidin or its derivatives.

[0023] The active ingredients are one or more of sodium cantharidate, norcantharidin, methylcantharidin and hydroxycantharidin.

[0024] The in-situ gel preparation can be an injection preparation or an external use preparation.

[0025] When the subcutaneous local injection is used to treat molluscum contagiosum, the injection preparation is a liquid at room temperature, and the liquid injection preparation is converted into a gel state due to the temperature rise when the injection is injected subcutaneously, so that the drug is released for a long time in the local wart body, and the treatment effect is enhanced.

[0026] When the external use is used to treat molluscum contagiosum, the drug is applied to the wart body of molluscum contagiosum by using a micro-quantitative drug delivery device, and the drug is quickly converted into a gel state under the action of temperature, so that the drug can be conveniently applied and effectively prevented from overflowing, thereby reducing the damage of the drug to the surrounding skin.

[0027] The specific components and preparation method of the drug composition as the in-situ gel injection preparation are described below.

[0028] Example 1 This example discloses an in-situ release cantharidin drug composition, and the active ingredient in the drug composition is cantharidin. The prescription for preparing 1000 preparation units is as follows: The preparation method of the in-situ release cantharidin drug composition comprises the following steps: S1. In a sterile environment, take the prescription amount of about 560 ml of water for injection, add disodium edetate, and then add about 100 ml of ethanol solution, stir uniformly, and perform sterile filtration through a 0.22 μm filter membrane.

[0029] S2. In a sterile environment, weigh poloxamer 407 and poloxamer 188 into the solution in step S1, stir until a clear and uniform liquid is obtained, and control the process temperature at 15°C.

[0030] S3. In a sterile environment, control the water temperature at 15°C; then weigh the prescription amount of cantharidin, add the remaining amount of ethanol, acetone, and the remaining amount of water for injection to dissolve, and then add benzyl alcohol and butylated hydroxytoluene, stir to dissolve, perform sterile filtration through a 0.22 μm filter membrane, and wait for use.

[0031] S4. Mix the two solutions in steps S2 and S3 together, stir uniformly, and fill into a quantitative syringe to obtain the product.

[0032] Example 2 This example discloses an in-situ release cantharidin drug composition, and the active ingredient in the drug composition is cantharidin. The prescription for preparing 1000 preparation units is as follows: The preparation method of the in-situ release cantharidin drug composition comprises the following steps: S1. In a sterile environment, take the prescription amount of about 560 ml of water for injection, add disodium edetate, and then add about 100 ml of ethanol solution, stir uniformly, and perform sterile filtration through a 0.22 μm filter membrane.

[0033] S2. In a sterile environment, weigh poloxamer 407 and poloxamer 188 into the solution in step S1, stir until a clear and uniform liquid is obtained, and control the process temperature at 15°C.

[0034] S3. In a sterile environment, control the water temperature at 15°C; then weigh the prescription amount of cantharidin, add the remaining amount of ethanol, acetone, and the remaining amount of water for injection to dissolve, and then add benzyl alcohol and butylated hydroxytoluene, stir to dissolve, perform sterile filtration through a 0.22 μm filter membrane, and wait for use.

[0035] S4, the two solutions in steps S2, S3 are mixed together, stirred uniformly, and filled into a quantitative syringe, to obtain the in-situ release drug composition of cantharidin.

[0036] Example 3 The present example discloses an in-situ release drug composition of cantharidin, and the active ingredient in the drug composition is cantharidin. The prescription for preparing 1000 preparation units is as follows: The preparation method of the in-situ release drug composition of cantharidin comprises the following steps: S1, in a sterile environment, take the prescription amount of about 560 ml of water for injection, add disodium edetate, then add about 100 ml of ethanol solution, stir uniformly, and perform sterile filtration with a 0.22 μm filter membrane.

[0037] S2, in a sterile environment, weigh poloxamer 407 and poloxamer 188 and dissolve them in the solution in step S1, stir until a clear and uniform liquid is obtained, and the process temperature is controlled at 15°C; S3, in a sterile environment, control the water temperature at 15°C; then weigh the prescription amount of cantharidin, add the remaining amount of ethanol, acetone, and the remaining amount of water for injection to dissolve it, then add nipagin methyl ester and sodium metabisulfite, stir to dissolve, and perform sterile filtration with a 0.22 μm filter membrane, ready for use; S4, the two solutions in steps S2, S3 are mixed together, stirred uniformly, and filled into a quantitative syringe, to obtain the in-situ release drug composition of cantharidin.

[0038] Viscosity and rheological property test of in-situ release drug gel The viscosity of the in-situ release drug gel of cantharidin prepared in Example 1 and the commercially available preparation (commercially available 5-fluorouracil ointment) at different temperatures was tested by using a digital viscometer, and the specific data are shown in Table 1.

[0039] Table 1: From the test results, it can be seen that the viscosity of the preparation in Example 1 of the present application gradually increases with the increase of temperature, while the viscosity of the commercially available preparation changes little, indicating that the viscosity is greatly affected by temperature and can play a role in sustained release.

[0040] The above only describes some embodiments of the present application, and it should be noted that, for those skilled in the art, other modifications and improvements can be made without departing from the inventive concept of the present application, and these all belong to the protection scope of the present application.

Claims

1. A cantharidin in situ releasing pharmaceutical composition, characterized in that, The pharmaceutical composition contains 0.1-2% of active ingredients, 0.5-3% of gel matrix, 0.1-3% of stabilizer, 0.1-1% of bacteriostatic agent and solvent; the active ingredients contain cantharidin or its derivatives.

2. The pharmaceutical composition of claim 1, wherein, The active ingredients are one or more of sodium cantharidate, norcantharidin, methylcantharidin and hydroxycantharidin.

3. The pharmaceutical composition of claim 2, wherein, The gel matrix is one or a mixture of poloxamer 407 and poloxamer 188.

4. The pharmaceutical composition of claim 3, wherein, The stabilizer is a mixture of one or more of disodium edetate, sodium bisulfite, sodium sulfite, sodium metabisulfite and butylated hydroxytoluene.

5. The pharmaceutical composition of claim 1, wherein, The bacteriostatic agent is one or more of phenol, cresol, chlorocresol, chlorobutanol, phenylmercuric nitrate, benzyl alcohol and nipagin.

6. The pharmaceutical composition of claim 5, wherein, The solvent is one or more of water, ethanol, isopropyl alcohol and acetone.

7. The pharmaceutical composition of claim 6, wherein, The pharmaceutical composition is a in-situ gel preparation.

8. Process for the preparation of a pharmaceutical composition according to any one of claims 1 to 7, characterized in that, The preparation method comprises the following steps: S1. Under a sterile environment, take 80% of the prescribed amount of solvent, add stabilizer, then add an appropriate amount of ethanol solution, stir until uniform, and perform sterile filtration; S2. Dissolve the gel matrix in the solution of step S1, stir until a clear and uniform liquid is obtained, and control the process temperature at 10-20℃; S3. Under a sterile environment, control the water temperature at 10-20℃; add an appropriate amount of solvent to the active ingredients to dissolve them, then add the bacteriostatic agent and stabilizer, stir to dissolve, and perform sterile filtration; S4. Mix the two solutions of steps S2 and S3, stir until uniform, and obtain the cantharidin in-situ release pharmaceutical composition.